Brean Capital initiates coverage on Biogen (NASDAQ: BIIB) with a Buy. PT $184.00.

The firm comments, "In 2011, two ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE